Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
  • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
  • Y10S530/864—Monoclonal

Definitions

• This invention relates to monoclonal antibodies, to hybridoma cells for producing such antibodies, and to in vitro methods for detecting or for lysing NK or NK-like cells using such antibodies.
• NK cells Human peripheral blood contains a sub-population of mononuclear cells called natural killer (NK) cells, which are defined by their ability to lyse tumour cells in vitro in the absence of antibody or previous immunization.
• N901 a monoclonal antibody to NK cells
• N901 a monoclonal antibody to NK cells
• the antibody is incapable of lysing NK cells and NK-like cells in vi'tro in the presence of complement.
• NK-like cells refers to cells found elsewhere than in normal peripheral blood, e.g., cultured NK cells, or cells in other organs or in malignancies, and either having the lytic capability of NK cells, or bearing a surface antigenic determinant specific to NK cells.
• the invention features, in one aspect thereof, a monoclonal antibody capable of lysing human NK cells in vitro in the presence of complement.
• the antibody is unreactive with non-NK human granulocytes, non-NK human monocytes, human red blood cells, human platelets, human thymocytes, and non-NK human T3 lymphocytes; the antibody is of the IgM or IgG 2 isotype; and it recognizes an approximately 200,000-220,000 dalton NK cell-specific antigenic determinant on the surface of substantially all NK cells (that particular antigenic determinant is referred to herein as "NKH1 A ".)
• the antibody can be labeled, e.g. with a radioactive or fluorescent label, and used to identify NK cells and to distinguish these cells from non-NK cells.
• the antibody can also be used to destroy NK cells in tissue, e.g., bone marrow to be infused in a patient, to inhibit graft-versus-host disease.
• monoclonal antibodies having the above specificity and characteristics are encompassed by the present invention. These monoclonal antibodies may be produced by hybrid cells made using conventional hybridisation and screening techniques such as are described by Reinherz et al. in (1979) J. Immunol. 123, 1312 and Ritz et al. in Nature (1980) 283, 583. the disclosures of both of which are hereby incorporated by reference. As is well-known in the monoclonal antibody field, each independently-produced hybrid cell line that produces a monoclonal antibody specific to the same particular antigenic determinant is nonetheless different from all others, as is each of the monoclonal antibodies so produced.
• the invention provides the monoclonal antibody produced by the hybridoma cell ATCC HB 8564.
• the invention in this aspect extends to the hybridoma cell itself.
• a method of detecting the presence of NK or NK-like cells in a cell-containing clinical sample taken from a human characterised in that it comprises the steps of contacting said sample with an antibody according to the invention, and detecting immune complexes as an indication of the presence of said cells.
• a method of lysing NK cells or NK-like cells in a clinical sample characterised in that it comprises incubating said sample with an antibody according to the invention in the presence of complement.
• JT3 clone was derived from purified large granular lymphocytes (LGL) initially stimulated with PHA and medium containing interleukin-2.
• LGL large granular lymphocytes
• JT3 cells have been maintained in culture and have been found to display stable phenotype (T3-T4-T8-T11+N901+) and cytotoxic activity when tested against a large panel of in vitro established cell lines.
• the JT3 clone was generated according to the limited dilution method described in Hercend et al. (1982) J. Immunol. 129. 1299 and Hercend et al. (1983) Nature 301. 158.
• the method involved cloning LGL at one cell/well on a feeder layer of autologous irradiated (5000 rad) human peripheral blood mononuclear cells (PBMC) plus either PHA (2 ug/ml) or allogeneic or autologous irradiated (5000 rad) EBV transformed B cells. Selected colonies were expanded by addition of culture medium containing LCM (10-15% final dilution) every 3 days.
• Culture medium was RPMI 1640 supplemented with 1% penicillin-streptomycin, 1% sodium pyruvate, 20% human AB serum.
• the JT3 line was subsequently subcloned 2 times at 100 cells/well on a feeder layer of autologous irradiated PBMC plus irradiated EBV transformed B cells. Following subcloning procedures, both phenotype and cytotoxic function have remained stable.
• the immunization schedule consisted of an initial intraperitoneal injection of 4 x 10 JT3 cells emulsified in complete Freund's adjuvant (Difco, Detroit. MI) followed by two weekly intraperitoneal injections of 4 x 10 6 viable cells in phosphate buffered saline (PBS). Two weeks later. 2 x 1 0 6 cells were injected intravenously, followed by splenectomy 3 days later. Somatic cell hybridization was carried out by the method of Kohler and Milstein (1975) Nature 256. 495.
• the initial screening of hybridoma supernatants was carried out as follows: 10,000 51 Cr labeled JT3 cells were incubated with an aliquot of each hybridoma supernatant for 30 minutes at room temperature in V bottom microtiter plates. Rabbit complement at an appropriate non-toxic dilution (usually 1:10) was then added for 1 hour at 37 C. Subsequently, plates were spun down and antibody reactivity was measured as release of 51 Cr into the supernatants using a gamma scintillation counter. Positive supernatants were then tested under identical experimental conditions against an autologous MHC restricted cytotoxic T cell clone as well as an autologous EBV transformed B cell line.
• the reactivity pattern of the antibody was determined by testing on purified populations of lymphoid and nonlymphoid cells by indirect immunofluorescence assays and subsequent analysis using either a FACS I or Epics V flow cytometer.
• PBMC peripheral blood mononuclear cells
• F/H Ficoll-Hypaque
• Monocyte enriched adherent cells were obtained from PBMC by two step adherence on plastic culture dishes.
• Granulocytes were isolated from F/H gradient pellets using high molecular weight dextran.
• Activated T cells were generated by stimulating E+ cells with phytohemagglutinin (PHA) (2 pg/ml) and tested on day 7 following stimulation.
• PHA phytohemagglutinin
• the antibody was found to be strongly reactive with JT3 immunizing cells. In addition, as shown in the Table below, it was found to react with a small (12%) population of lymphocytes present in peripheral blood. Human monocytes. granulocytes, platelets, red blood cells, thymocytes, T3 lymphocytes, and PHA activated E+ cells were negative.
• NKH1 A + cells in unstimulated peripheral blood was determined following purification of these cells by immunofluorescence cell sorting.
• peripheral blood lymphocytes from two individual donors were incubated with anti-NKHl A plus GM-FITC.
• Small numbers (about 50,000) of NKH1 A + cells were then purified-using an Epics V cell sorter and cytocentrifuge smears were prepared and analyzed. It was found that NKH1 A + purified fractions consisted almost entirely (over 90%) of large granular lymphocytes.
• anti-NKHl A is an IgM antibody
• peripheral blood mononuclear cells were incubated with either medium or anti-NKHI A for 30 minutes at room temperature.
• Anti-N901 (discussed above), which is a nonlytic IgG 1 antibody directed at NK cells, was used as a control in these experiments. Antibody excess was washed out and complement was then added for 45 minutes at 37C. This procedure was repeated two times. Subsequently, remaining viable cells were counted and 51 Cr labeled target cells were added.
• This procedure was used on PBL target cells from a donor displaying a very high level of spontaneous cytotoxicity against a T cell leukemia line, indicating the presence of many NK cells.
• Immunoprecipitation experiments were conducted to identify the molecular weight of the antigen defined by anti-NKHl A . .
• the immunoprecipitations were done using preformed complexes of rabbit anti-mouse Ig with anti-NKHl A . These preformed complexes were reacted with 125 I surface labeled JT3 cell lysates which were precleared 3 times by incubation at 4 C for 1 hour with either formalin fixed Staph A bacteria and/or preformed complexes of rabbit anti-mouse Ig nonspecific monoclonal antibody. Aliquots of precleared lysate were then incubated with specific preformed complexes for 2 hours at 4 C.
• Immune precipitates were then washed 4 times with RIPA buffer and dissolved in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and loaded onto separate slots on a 10% polyacrylamide slab gel. Identical aliguots of immune precipitation were run in nonreduced and reduced conditions after addition of 2 mercaptoethanol to SDS-PAGE sample buffer. Gels were dried and radiolabeled precipitates were visualized using standard methods. Anti-NKHl A precipitated a broad band at approximately 200-220KD. Additional experiments were performed in which the precipitates were analyzed using a 5-15% polyacrylamide gradient and no additional specific bands were identified. When gradient gels were used, the specific band was seen at a slightly lower molecular weight (180-200KD) as compared to the 10% polyacrylamide gels.
• SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
• anti-NKH1 A and anti-N90l are probably directed at the same NK surface antigen molecule, in a series of competitive binding experiments.
• isotype specific FITC in indirect immunofluorescence assays, it was found that anti-N901 effectively blocked binding of anti-NKHl A whereas anti-NKHl A did not significantly affect binding of anti-N901.
• the monoclonal antibody of the invention can be used to identify NK and NK-like cells in peripheral blood samples and in samples from other tissue, e.g. bone marrow.
• the antibody can be used to detect such cells in clinical samples using any conventional immunoassay technique, e.g., indirect immunofluorescence or a direct assay employing antibody labeled, e.g., with a radioactive label.
• any conventional immunoassay technique e.g., indirect immunofluorescence or a direct assay employing antibody labeled, e.g., with a radioactive label.
• the antibody can also be used to detect NK or NK-like cells, or cell-free antigen, in plasma and other body fluids in vitro.
• Detecting and quantifying circulating NK cells can permit correlations between various disease states and numbers of NK cells; such information can in turn further elucidate the role of NK cells in healthy and sick individuals, a role which, evidence now suggests, may include the destruction of malignant cells.
• the antibody of the invention can be useful in combatting GVHD by killing associated NK cells.
• the antibody plus complement can be used to treat the bone marrow prior to transplantation, according to conventional techniques, to kill the NK cells which could otherwise contribute to rejection of the host by the bone marrow.
• the ability of the antibody to lyse NK cells in the presence of complement is a function of its being of the IgM isotype; generally, only IgM and IgG 2 antibodies possess this property.
• the kill rate of NK cells in tissue can be increased by employing antibody to which has been coupled, using conventional techniques, a cytotoxic agent such as ricin or adiamycin.
• NK cells may also prove useful in the treatment of autoimmune diseases such as SLE which are in part mediated by NK cells.
• the antibody may also prove useful in inhibiting the rejection of allografts such as bone marrow and kidneys by using anti-NKHl to inactivate host NK cells which would otherwise attack the allograft.
• Another use of the antibody is in the purification of NK cells from peripheral blood or from a cell suspension of hematopoietic tissue, e.g. bone marrow, or lymphoid tissue, e.g. thymus, spleen, or lymph node tissue.
• the antibody can be used for such purification in connection with any conventional cell separation technique, e.g. cell sorting, immune rosetting, panning, or immune affinity column chromotography.
• NK cells Such purification of NK cells can be useful where a particular medical disorder requires the infusion into the patient of NK cells, either from the patient or from a donor. Such infusion of NK cells can be used, e.g., to treat malignancies susceptible to attack by NK cells.
• a patient's own NK cells for such treatment.
• anti-NK is used to purify NK cells from the patient's blood or other tissue
• a selected NK cell can be cultured and expanded and then reinfused into the patient; appropriate culture methods are described in Hercend et al. (1982) J. Immunol. 129, 1299; and Hercend et al. (1983) Nature 301, 158, both hereby incorporated by reference.
• the antibody can be labeled in a variety of ways, e.g. with fluorescein-containing ligands, heavy metals, or C-containing compounds.

Landscapes

• Health & Medical Sciences (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Transplantation (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (3)

Family

ID=24414404

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (6)

Family Cites Families (5)

• 1984
  • 1984-04-23 US US06/603,181 patent/US4772552A/en not_active Expired - Lifetime
• 1985
  • 1985-04-22 DE DE8585302806T patent/DE3585049D1/de not_active Expired - Lifetime
  • 1985-04-22 AT AT85302806T patent/ATE71149T1/de not_active IP Right Cessation
  • 1985-04-22 CA CA000479685A patent/CA1271715A/fr not_active Expired - Lifetime
  • 1985-04-22 EP EP85302806A patent/EP0160486B1/fr not_active Expired - Lifetime
  • 1985-04-23 JP JP8735485A patent/JPS6128000A/ja active Granted
• 1992
  • 1992-12-02 JP JP4323131A patent/JPH0734742B2/ja not_active Expired - Fee Related

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events